ProShare Advisors LLC Boosts Stock Position in Boston Scientific Co. (NYSE:BSX)

ProShare Advisors LLC increased its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 12.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 224,880 shares of the medical equipment provider's stock after acquiring an additional 24,022 shares during the period. ProShare Advisors LLC's holdings in Boston Scientific were worth $20,086,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. TFC Financial Management Inc. lifted its position in shares of Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after buying an additional 210 shares in the last quarter. Colonial Trust Co SC increased its position in Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 260 shares during the period. Valley National Advisers Inc. lifted its holdings in Boston Scientific by 262.4% during the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after buying an additional 286 shares during the period. Fairway Wealth LLC acquired a new position in shares of Boston Scientific during the fourth quarter worth $36,000. Finally, Global Trust Asset Management LLC increased its position in shares of Boston Scientific by 64.5% in the 4th quarter. Global Trust Asset Management LLC now owns 436 shares of the medical equipment provider's stock valued at $39,000 after acquiring an additional 171 shares during the period. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

Shares of BSX stock traded down $0.14 on Tuesday, hitting $106.52. The company's stock had a trading volume of 7,906,901 shares, compared to its average volume of 6,374,666. Boston Scientific Co. has a fifty-two week low of $71.88 and a fifty-two week high of $107.36. The stock's 50 day moving average is $99.39 and its 200-day moving average is $96.90. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The company has a market capitalization of $157.59 billion, a PE ratio of 85.22, a PEG ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. During the same quarter in the prior year, the business earned $0.56 earnings per share. The business's revenue for the quarter was up 20.9% compared to the same quarter last year. Equities research analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,314 shares of the company's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total value of $1,767,066.84. Following the sale, the executive vice president now directly owns 22,235 shares of the company's stock, valued at $2,269,304.10. This represents a 43.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP John Bradley Sorenson sold 4,572 shares of the stock in a transaction on Monday, May 5th. The shares were sold at an average price of $104.54, for a total value of $477,956.88. Following the sale, the executive vice president now directly owns 18,705 shares in the company, valued at $1,955,420.70. This trade represents a 19.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 263,163 shares of company stock worth $27,129,540 in the last ninety days. Company insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on BSX shares. Needham & Company LLC increased their target price on shares of Boston Scientific from $113.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. Argus set a $130.00 target price on shares of Boston Scientific in a report on Tuesday, February 18th. BTIG Research reissued a "buy" rating and issued a $124.00 price target on shares of Boston Scientific in a research report on Wednesday, April 23rd. StockNews.com raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Finally, UBS Group boosted their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Twenty-three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Boston Scientific has a consensus rating of "Buy" and a consensus target price of $114.74.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.